Akesis and MagnetTx Announces Strategic Collaboration with CHS & OHS

Washington, D.C., October 9, 2024 — OHS and CHS today announced a strategic collaboration with Akesis during the 2024 ASTRO Annual Meeting. The relationship is designed to accelerate access to advanced, image-guided adaptive radiotherapy by pairing OHS’s turnkey oncology program with IMS’s enterprise implementation expertise for large medical facilities.

The collaboration will support healthcare providers in planning, financing, and deploying next-generation radiotherapy platforms, including systems supplied by industry partners such as Akesis and MagnetTx. By aligning clinical operations, site design and buildout, technology sourcing, and revenue-cycle support, OHS will help institutions focus on what matters most, their patients.

“OHS exists to convert innovation into impact for providers,” said OHS CEO Leonard Farber. “Partnering with OHS strengthens our ability to deliver a true turnkey program, from OpEx-friendly financing and facility readiness to clinical training and ongoing service.”

“OHS is excited about the opportunity for a true partnership, allowing our clients choices that meet current and future radiotherapy needs,” said Ron Sancho, Principal of OHS.

The OHS collaboration is intended to streamline the path from decision to first patient treated, supporting personalized care, operational efficiency, and sustainable growth for clinics, hospitals, and health systems.

About OHS

OHS delivers end-to-end oncology solutions that connect innovation to impact. The OHS turnkey program spans OpEx-forward financing, site design and construction, technology sourcing, isotope supply, revenue-cycle optimization, clinician education, and comprehensive service coverage.